Tempus AI annual ebitda
2022
2023
2024
2025
Tempus AI EBITDA Growth & History (TEM)
Tempus AI's calculated EBITDA was −$220.8M for fiscal 2025.
View full Tempus AI company overviewTempus AI annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$220.8M | $443.9M | — |
| 2024 | 2024-12-31 | −$664.7M | −$490.2M | — |
| 2023 | 2023-12-31 | −$174.5M | $73.8M | — |
| 2022 | 2022-12-31 | −$248.4M | — | — |
Tempus AI quarterly ebitda
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$68.8M | −$15.4M | — |
| Q1 2026 | 2026-03-31 | −$77.3M | −$16.5M | — |
| Q4 2025 | 2025-12-31 | −$53.7M | −$9.9M | — |
| Q3 2025 | 2025-09-30 | −$52.9M | −$6.0M | — |
| Q2 2025 | 2025-06-30 | −$53.4M | $473.6M | — |
| Q1 2025 | 2025-03-31 | −$60.8M | −$13.8M | — |
| Q4 2024 | 2024-12-31 | −$43.8M | — | — |
| Q3 2024 | 2024-09-30 | −$46.8M | −$7.5M | — |
| Q2 2024 | 2024-06-30 | −$527.1M | −$487.1M | — |
| Q1 2024 | 2024-03-31 | −$47.0M | — | — |
| Q3 2023 | 2023-09-30 | −$39.3M | — | — |
| Q2 2023 | 2023-06-30 | −$39.9M | — | — |
Tempus AI ebitda trends
Between the periods ended 2022-12-31 and 2025-12-31, Tempus AI's ebitda increased from −$248.4M to −$220.8M, a change of $27.5M. The latest reported quarter, Q2 2026, shows −$68.8M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Tempus AI source filings ↗Community posts
Tempus secures European IVDR certification for its RNA tumor-profiling assay
Tempus ($TEM) received certification for its xR assay under the European Union’s In Vitro Diagnostic Regulation as a Class C diagnostic device. The certification also covers its quality management system for cancer genomic profiling with ne ...
Tempus gains FDA clearance for mitral-regurgitation screening AI
Tempus AI ($TEM) has received FDA 510(k) clearance for ECG-MR, software that examines standard resting 12-lead electrocardiograms for signs associated with previously undiagnosed moderate or severe mitral regurgitation. It is the company’s ...
Tempus plans disease-focused dataset covering 100,000 whole genomes
Tempus AI ($TEM) launched an initiative to build a research platform linking 100,000 whole-genome sequences with long-term clinical information over several years. The company intends to focus on disease populations and treatment outcomes, ...
